IP Library Granted Patent US 9,509,010
Granted Patent B2
US 9,509,010 · App. 14/752,448 · Granted Nov 29, 2016

Biological fuel cell and methods

Inventor: Adam Heller (Austin, TX)
Assignee: Abbott Diabetes Care Inc.
H01M8/16H01M4/9008H01M2250/30Y02B90/18Y02E60/527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,509,010
App. No.
14/752,448
Granted
Nov 29, 2016
Kind
B2
Abstract

A fuel cell has an anode and a cathode with anode enzyme disposed on the anode and cathode enzyme is disposed on the cathode. The anode is configured and arranged to electrooxidize an anode reductant in the presence of the anode enzyme. Likewise, the cathode is configured and arranged to electroreduce a cathode oxidant in the presence of the cathode enzyme. In addition, anode redox hydrogel may be disposed on the anode to transduce a current between the anode and the anode enzyme and cathode redox hydrogel may be disposed on the cathode to transduce a current between the cathode and the cathode enzyme.

Claims (21)

1. An electrochemical cell for positioning in a biological system comprising oxygen, comprising:

a substrate comprising a first face and a second face;

an anode disposed on the first face of the substrate, wherein the anode comprises a crosslinked anode enzyme and polymer and the anode further comprises a mediator comprising a transition metal complex; and

a cathode disposed on the second face of the substrate.

2. The electrochemical cell according to claim 1 , wherein the transition metal complex comprises ruthenium or osmium.

3. The electrochemical cell according to claim 1 , wherein the anode comprises a conductive material selected from the group consisting of gold, carbon, platinum, ruthenium dioxide and palladium.

4. The electrochemical cell according to claim 3 , wherein the anode comprises carbon or gold.

5. The electrochemical cell according to claim 1 , wherein the substrate surface is roughened.

6. The electrochemical cell according to claim 1 , wherein the anode enzyme is a glucose-responsive enzyme.

7. The electrochemical cell according to claim 6 , wherein the glucose-responsive enzyme is glucose oxidase or glucose dehydrogenase.

8. The electrochemical cell according to claim 6 , wherein the glucose-responsive enzyme further comprises an enzyme cofactor.

9. The electrochemical cell according to claim 8 , wherein the enzyme cofactor is pyrroloquinoline quinone (PQQ).

10. The electrochemical cell according to claim 1 , wherein the cathode comprises platinum.

11. The electrochemical cell according to claim 1 , wherein the cathode further comprises a cathode enzyme.

12. The electrochemical cell according to claim 11 , wherein the cathode enzyme is an enzyme selected from the group consisting of tyrosinase, horseradish peroxidase, soybean peroxidase, laccase and cytochrome C peroxidase.

13. The electrochemical cell according to claim 12 , wherein the cathode enzyme is laccase or cytochrome C peroxidase.

14. The electrochemical cell according to claim 1 , wherein at least a portion of the electrochemical cell is configured to be subcutaneously positioned in a subject.

15. The electrochemical cell according to claim 1 , wherein the electrochemical cell further comprises a mass transport limiting membrane disposed over the anode and cathode.

16. The electrochemical cell according to claim 15 , wherein the mass transport limiting membrane is configured to limit contact of macromolecules of 5000 daltons or greater with the anode and cathode.

17. The electrochemical cell according to claim 15 , wherein the mass transport limiting membrane is a hydrogel.

18. The electrochemical cell according to claim 17 , wherein the hydrogel comprises at least 20 wt % fluid when in equilibrium with analyte-containing fluid.

Assignments (5)
CHANGE OF NAME Recorded Apr 12, 2017
From: THERASENSE, INC.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 042241/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2015
From: HELLER, ADAM
To: E. HELLER & COMPANY
Reel/Frame 036448/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2015
From: E. HELLER & COMPANY
To: THERASENSE, INC.
Reel/Frame 036448/0615 →
RATIFICATION OF ASSIGNMENT Recorded Aug 28, 2015
From: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM; THERASENSE, INC.
To: THERASENSE, INC.
Reel/Frame 036503/0821 →
CHANGE OF NAME Recorded Aug 28, 2015
From: THERASENSE, INC.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 036504/0891 →
Continuity (13)
Continuation 14543480 · Nov 17, 2014
Continuation 14218589 · Mar 18, 2014
Continuation 13862153 · Apr 12, 2013
Continuation 13567903 · Aug 6, 2012
Continuation 12944551 · Nov 11, 2010
Continuation 12876816 · Sep 7, 2010
Continuation 11768560 · Jun 26, 2007
Continuation 11277696 · Mar 28, 2006
Division 10385069 · Mar 10, 2003
Continuation 09961621 · Sep 24, 2001
Continuation 09203227 · Nov 30, 1998
Provisional Application 60089900 · Jun 17, 1998
Related Publication 20150295264A1 · Oct 15, 2015